its up to the FDA, and right now, these specific peptides sit outside it. The biggest risk to this potential pathway, Robinson explains, is reporting of adverse events, which the FDA describes as any undesirable experience associated with the use of a medical product in a patient. Should an adverse event happen, Robinson says it could negatively impact or delay the rulemaking process. As the FDA pointed out in their official meeting recommendation to keep the peptides under their current restrictions, these peptides simply dont have adequate clinical data behind them
I am so glad I found this
It helps with the formation of red blood cells, energy metabolism and cell division
When we pulled product pages, Koi published per-batch COAs most prominently
CO 2 Laser-Resurfaced Skin Miller et al., Archives of Facial Plastic Surgery (2006) Miller and colleagues evaluated the effect of topical copper-tripeptide complex on wound healing following carbon-dioxide laser facial resurfacing a procedure that creates a controlled superficial burn requiring extended recovery and characterized by prolonged post-treatment erythema